Senator blasts GlaxoSmithKline-sponsored herpes med ed

The chairman of the Senate Committee on Aging has written the Accreditation Council for Continuing Medical Education (ACCME) complaining that GlaxoSmithKline, which makes Valtrex, “sponsors CME events which promote testing all pregnant women for herpes.” 

Sen. Herb Kohl's office did not name GSK in the letter but told MM&M that it was the company cited and forwarded a link to a March 22, 2006, webcast, hosted by Medscape and titled Genital herpes and pregnancy: Prevention and management strategies for healthcare providers.

“However, routine testing for herpes in pregnancy is not recommended by any scientific evidence or any national expert panel,” wrote Kohl in a June 20 letter to ACCME chief Murray Kopelow, adding that the American College of Obstetricians and Gynecologists, the CDC and the US Preventative Services Task Force all reject prenatal testing “due to the dearth of evidence that exists to recommend routine screening and the potential harm to many low-risk women and fetuses from the side effects of antiviral therapy.”

Kohl said he was “troubled by any attempt to persuade physicians to use a drug treatment for any reason other than the patient's condition and the drug's effectiveness in treating it.” He asked ACCME to furnish: a written description of ACCME's accreditation process for CME courses; any criteria ACCME uses as part of that process regarding scientific validity of course content; any mechanisms ACCME has in place to ensure that no undue influence by any industry is being exerted through CME courses; and any further plans ACCME may have in place to develop such mechanisms. 
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters


Investment in healthcare IT stands at an all-time high. The government has spent billions to promote EHR adoption. Yet the physician wish list is a mile long, while hospitals and patients are not where they need to be. To peel back the layers of what we've all been waiting for in the Great Data Capture of the 21st Century, and to review the changes enabling the healthcare data ecosystem to coexist, MM&M presents this e-Book. Click here.


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.